Baxter International Inc.  (BAX) Trade Now »     Rate BAX  -  Discuss BAX  -  Add to Watch List        

Home

Analysis & Videos

Quotes

Bull or Bear

Discuss

BAX Analysis & Videos »


BAX: Bull or Bear?

Turnaround expert targets laggard pharmaceuticals BAX

-0.91% in 31 days Filed under: Newsletters, Abbott Laboratories (ABT), Baxter Intl (BAX), Bristol-Myers Squibb (BMY), Gilead Sciences (GILD), Stocks to Buy "Being contrarians, we are always looking for laggard stocks with the potential to rebound," says turnaround expert George Putnam. In his The Turnaround Letter, the advisor reviews four medical and pharmaceutical stocks that have been among the worst performers in the S&P 100 since the market bottom. Despite their poor performance, he thinks they may be due for a rebound. <>"We think that investors who got left behind by the first leg of the market rally are s... Continue reading »

By  Steven Halpern   (+4.67%  risk: moderate)  10/12/09

Comment

Consider Baxter: Its products don't go out of style BAX

+6.15% in 117 days Filed under: Stocks to Buy I'm reiterating my Buy rating for Baxter (NYSE: BAX) first recommended on March 13, 2009 at a price of $51.16. Baxter's near-recession-proof story remains intact. Baxter, a maker of a variety of medical products across three divisions, including drugs and vaccines, dialysis equipment, and IV supplies, should record a FY2009 revenue increase of 2-4%, led by demand for recombinants, plasma proteins, and antibody therapies in its bioscience unit. Continue reading Consider Baxter: Its products don't go out of style <>Consider Baxter: Its products don't go out of style orig... Continue reading »

By  Joseph Lazzaro   (+1.68%  risk: moderate)  07/18/09

Comment

Javelin Pharma: Late-Stage Pipeline Targets Pain BAX

73%

+11.63% in 242 days Javelin Pharma: Late-Stage Pipeline Targets Pain   Javelin Pharma (JAV) is focused on the late stage clinical development of three Phase 3 compounds while seeking partnerships for a non-dilutive source of funding. In mid-January, JAV established a partnership for Dyloject (injectable diclofenac) with Therabel Pharma to market the drug in Europe, where it is already approved for use.   http://biomedreports.com/fda-calendar.html   <> The deal is worth up to $71M (with $12M in upfront cash and $59.5M in sales/regulatory milestones) and extends Javelin'... Continue reading »

By  Mike Havrilla   (+1.04%  risk: conservative)  03/15/09

Comment

Baxter is one company that's on the mend BAX

+7.50% in 127 days (closed on 07/18/09) Filed under: Baxter Intl (BAX), Stocks to Buy The Dow's difficult start in 2009, following on the heels of 2008's awful performance, has done little to attract new money into the market. And neither has the U.S. economy, which remains entrenched in a pronounced recession, with few signs that it's bottomed. The economic conditions invalidate most sectors, but there are a few that offer promise. One is health care, which is why Baxter International (NYSE: BAX) is worth a review. Continue reading Baxter is one company that's on the mend <>Baxter is one company that's on the mend originally appeared... Continue reading »

By  Joseph Lazzaro   (+1.68%  risk: moderate)  03/13/09

Comment

ETFI Health Innovators Index: Does R&D Lead to Higher Stock Prices? BAX

73%

-13.49% in 122 days (closed on 03/15/09) ETFI Health Innovators Index: Does R&D Lead to Higher Stock Prices? <> <> The accompanying table includes statistics and the top five rated companies in the ETFI Global Health Innovators Index of companies with market caps over $100M which received FDA approval in the trailing 12-month period for either an original new drug or medical device product. The index includes companies which get approvals for drugs or biological agents classified as new chemical entities (i.e. excluding reformulations of existing drugs, generic drugs, and label extensions for existing produc... Continue reading »

By  Mike Havrilla   (+1.04%  risk: conservative)  11/12/08

Comment

Expanding Defensive Growth Index into Europe BAX

73%

+0.12% in 20 days (closed on 11/12/08) Expanding Defensive Growth Index into Europe <> <> The accompanying table presents an updated version of the ETFI Highly Defensive PerformIdex, which is expanded to 40 companies with market caps of at least $10B from the industry groups listed below. This defensive growth index is heavily weighted in consumer staples and healthcare and is now structured to include companies based in Europe, in addition to the United States and Canada. Compared to the previous version, this index has a lower beta and higher average market cap and adds European companie... Continue reading »

By  Mike Havrilla   (+1.04%  risk: conservative)  10/23/08

Comment

Bullish on BAX ... BAX

62%

-12.07% in 487 days Analysts' Recommendation: Buy 30 Days Ago: Buy Analysts' Target: $70 Analysts' Targets Leerink Swann & Company $70 Outperform Monday, June 23, 2008 Baxter International, Inc. operates as a healthcare company worldwide. It offers medical devices, pharmaceuticals, and biotechnology products for the treatment of hemophilia, immune disorders, cancer, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. The company operates through three segments: BioScience, Medication Delivery, and Renal. The BioScience segment manufactures ... Continue reading »

By  Marian Filo   (-24.55%  risk: aggressive)  07/12/08

Comment

Large cap medical products and services company BAX

9 %

-3.24% in 28 days (closed on 03/26/08) http://money.cnn.com/news/newsfeeds/articles/apwire/165fb1f58... Baxter is a medical services company headquartered in Deerfield IL with three divisions -bioscience,renal and medical devices segment.The company has a diversfied product line, a growing market,patent protection and the cost advantage from a falling dollar.The stock is a bit richly valued at pe 23.1 pb 5.53 but is relatively debt free(0.447 debt-equity ratio). Continue reading »

By  Thomas George   (-4.58%  risk: moderate)  02/27/08

Comment

Baxter International (BAX) BAX

36%

-3.52% in 755 days Hello Friends! Thanks so much for stopping by and visiting my blog, Stock Picks Bob's Advice ! As always, please remember that I am an amateur investor, so please remember to consult with your professional investment advisers prior to making any investment decisions based on information on this website. <> Please excuse my recent political digression. But I plan to share with you thoughts on other things besides stocks from time to time when I am so inspired. I look forward to your comments and responses! We certainly will not all agree about all things but I would encourage you t... Continue reading »

By  Robert Freedland   (-5.24%  risk: aggressive)  10/18/07

Comment

People Bullish on BAX

Steven Halpern Tracked Blogger 56% about 1 mo ago	dfhutch Analyst N/A 2 mos ago	lila Analyst N/A 3 mos ago
Joseph Lazzaro Tracked Blogger 43% 3 mos ago	tango0123 Analyst N/A 4 mos ago

People Bearish on BAX

sdepatie Analyst N/A 6 days ago

traderthoughts Associate  4 % over 2 years ago

... more »  

None of the information contained on SocialPicks.com constitutes a recommendation by SocialPicks or its users that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. SocialPicks is not responsible for the posts, discussions, and recommendations of the users on the Site. SocialPicks does not provide investment advice. You must make your own independent decisions regarding any security, portfolio of securities, transaction, or investment strategy mentioned on the website. SocialPicks' users' past results are not necessarily indicative of future performance. Neither SocialPicks nor any of its users guarantees any specific outcome or profit, and you should be aware of the real risk of loss in following any strategy or investments discussed on the website. You understand and agree that you use the Site and Services at your own discretion and risk and that you will be solely responsible for any damages that arise from such use. Before acting on any information contained on the website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.